PE20020213A1 - DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a - Google Patents
DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2aInfo
- Publication number
- PE20020213A1 PE20020213A1 PE2001000615A PE2001000615A PE20020213A1 PE 20020213 A1 PE20020213 A1 PE 20020213A1 PE 2001000615 A PE2001000615 A PE 2001000615A PE 2001000615 A PE2001000615 A PE 2001000615A PE 20020213 A1 PE20020213 A1 PE 20020213A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ilo
- cycloalkyl
- phenyl
- adenosine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
Abstract
SE REFIERE A DERIVADOS DE PURINA O DERIVADOS DE 2-AMINOALQUIL-9-(TETRAHIDRO-2-FURANIL)-9H-PURINA DE FORMULA I DONDE R1 ES H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON FENILO, NAFTILO; R2 ES H, ALQUILO C1-C6; R3 Y R4 FORMAN JUNTO A N AZETIDINILO, PIRROLIDINILO, PIPERIDINILO, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C8, BENCILO, ENTRE OTROS; R5 ES CH2OH; CONR14R14; R6 Y R7 SON H, ALQUILO C1-C6 O JUNTO A N FORMAN AZETIDINILO, PIRRROLIDINILO, ENTRE OTROS; R8 ES AZETIDIN-1-ILO, PIRROLIDIN-1-ILO, PIPERIDIN-1-ILO, ENTRE OTROS; R9 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C8, FENILO; R10 ES ALQUILO C1-C6, CICLOALQUILO C3-C8, FENILO; R11 ES ALQUILO C1-C6, CICLOALQUILO C3-C8, BENCILO; R12 ES ALQUILO C1-C6, CICLOALQUILO C3-C8, FENILO, CONR9R9, COOR10, ENTRE OTROS; R13 ES FENILO, PIRIDIN-2-ILO, ENTRE OTROS; R14 ES H, ALQUILO C1-C6; R15 ES AZETIDIN-3-ILO, PIRROLIDIN-3-ILO, PIPERIDIN-3-ILO; m ES 0-2; X ES CH2, CH2CH2; Y ES CO, CS, SO2, C=N(CN). UN COMPUESTO PREFERIDO ES N-{(9-[2R,3R,4S,5R)-3,4-DIHIDROXI-5-(HIDROXIMETIL)-TETRAHIDRO-2-FURANIL]-6-[(2,2-DIFENILETIL)AMINO]9H-PURIN-2-IL)METIL)-N'-[2-(DIISOPROPILAMINO)ETIL]UREA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. LOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE ADENOSINA A2a AL INHIBIR LA FUNCION DE LOS NEUTROFILOS Y PUEDEN SER UTILES COMO AGENTES ANTIINFLAMATORIOS DEL TRACTO RESPIRATORIO COMO BRONQUITIS, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ASMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015727.1A GB0015727D0 (en) | 2000-06-27 | 2000-06-27 | Purine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020213A1 true PE20020213A1 (es) | 2002-03-19 |
Family
ID=9894500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000615A PE20020213A1 (es) | 2000-06-27 | 2001-06-25 | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a |
Country Status (42)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1421078B1 (en) | 2001-08-14 | 2006-09-27 | Eli Lilly And Company | Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes |
| SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| AU2003275257A1 (en) | 2002-09-26 | 2004-04-19 | Bristol-Myers Squibb Company | N-substituted heterocyclic amines as modulators of chemokine receptor activity |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| RU2007114887A (ru) * | 2004-09-20 | 2008-10-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Производные пурина и способы их применения |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Ｉｌ１３に対するヒト抗体および治療的使用 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| AR060607A1 (es) * | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
| US7589076B2 (en) * | 2006-05-18 | 2009-09-15 | Pgx Health, Llc | Substituted aryl piperidinylalkynyladenosines as A2AR agonists |
| US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
| CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
| US7897737B2 (en) | 2006-12-05 | 2011-03-01 | Lasergen, Inc. | 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing |
| BRPI0906838A2 (pt) | 2008-01-11 | 2015-07-14 | Novartis Ag | Pirimidinas como inibidores de quinase |
| CN102264917B (zh) | 2008-06-11 | 2015-06-10 | 激光基因公司 | 核苷酸和核苷以及将其用于dna测序的方法 |
| US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン |
| WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
| ES2894830T3 (es) | 2012-04-03 | 2022-02-16 | Novartis Ag | Productos combinados con inhibidores de tirosina·cinasa y su uso |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| ES2831416T3 (es) | 2014-07-31 | 2021-06-08 | Novartis Ag | Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8276187A (en) * | 1986-10-31 | 1988-05-25 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
| IL107101A0 (en) * | 1992-09-30 | 1993-12-28 | Merrell Dow Pharma | 2-substituted adenosines with a-2 receptor affinity |
| GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| AU2108299A (en) * | 1998-01-08 | 1999-07-26 | University Of Virginia Patent Foundation | A2A adenosine receptor agonists |
| CA2347512C (en) * | 1998-10-16 | 2005-12-06 | Pfizer Inc. | Adenine derivatives |
| GB9913932D0 (en) * | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| GB9924363D0 (en) * | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
| GB9924361D0 (en) * | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
-
2000
- 2000-06-27 GB GBGB0015727.1A patent/GB0015727D0/en not_active Ceased
-
2001
- 2001-06-14 PT PT01938490T patent/PT1296996E/pt unknown
- 2001-06-14 JP JP2002505798A patent/JP2004501929A/ja active Pending
- 2001-06-14 KR KR1020027017723A patent/KR20030036248A/ko not_active Application Discontinuation
- 2001-06-14 HU HU0301389A patent/HUP0301389A3/hu unknown
- 2001-06-14 PL PL36138401A patent/PL361384A1/xx not_active Application Discontinuation
- 2001-06-14 CZ CZ20023992A patent/CZ20023992A3/cs unknown
- 2001-06-14 OA OA1200200387A patent/OA12294A/en unknown
- 2001-06-14 ES ES01938490T patent/ES2220775T3/es not_active Expired - Lifetime
- 2001-06-14 WO PCT/IB2001/001064 patent/WO2002000676A1/en not_active Application Discontinuation
- 2001-06-14 DK DK01938490T patent/DK1296996T3/da active
- 2001-06-14 EA EA200201291A patent/EA200201291A1/ru unknown
- 2001-06-14 MX MXPA03000078A patent/MXPA03000078A/es active IP Right Grant
- 2001-06-14 SK SK1733-2002A patent/SK17332002A3/sk unknown
- 2001-06-14 TR TR2004/01622T patent/TR200401622T4/xx unknown
- 2001-06-14 IL IL15252901A patent/IL152529A0/xx unknown
- 2001-06-14 EP EP01938490A patent/EP1296996B1/en not_active Expired - Lifetime
- 2001-06-14 BR BR0111912-5A patent/BR0111912A/pt not_active IP Right Cessation
- 2001-06-14 EE EEP200200712A patent/EE200200712A/xx unknown
- 2001-06-14 AU AU2001264164A patent/AU2001264164A1/en not_active Abandoned
- 2001-06-14 CN CN01810621A patent/CN1432020A/zh active Pending
- 2001-06-14 DE DE60103537T patent/DE60103537T2/de not_active Expired - Fee Related
- 2001-06-14 AT AT01938490T patent/ATE267836T1/de not_active IP Right Cessation
- 2001-06-14 CA CA002412564A patent/CA2412564C/en not_active Expired - Fee Related
- 2001-06-14 NZ NZ521867A patent/NZ521867A/en unknown
- 2001-06-14 SI SI200130136T patent/SI1296996T1/xx unknown
- 2001-06-21 AP APAP/P/2001/002193A patent/AP1372A/en active
- 2001-06-21 GT GT200100119A patent/GT200100119A/es unknown
- 2001-06-22 DO DO2001000195A patent/DOP2001000195A/es unknown
- 2001-06-25 PE PE2001000615A patent/PE20020213A1/es not_active Application Discontinuation
- 2001-06-25 PA PA20018521001A patent/PA8521001A1/es unknown
- 2001-06-26 SV SV2001000507A patent/SV2002000507A/es not_active Application Discontinuation
- 2001-06-26 AR ARP010103038A patent/AR028759A1/es unknown
- 2001-06-26 TN TNTNSN01096A patent/TNSN01096A1/fr unknown
- 2001-06-26 UY UY26797A patent/UY26797A1/es not_active Application Discontinuation
-
2002
- 2002-10-07 BG BG107171A patent/BG107171A/xx unknown
- 2002-10-10 IS IS6580A patent/IS6580A/is unknown
- 2002-11-25 ZA ZA200209557A patent/ZA200209557B/en unknown
- 2002-12-12 NO NO20025975A patent/NO20025975L/no not_active Application Discontinuation
- 2002-12-12 HR HR20020995A patent/HRP20020995A2/hr not_active Application Discontinuation
- 2002-12-19 EC EC2002004396A patent/ECSP024396A/es unknown
- 2002-12-20 MA MA26970A patent/MA26918A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020213A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| PE20010430A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| PE20010755A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| RU2373209C2 (ru) | Пирролотриазиновые соединения как ингибиторы киназ | |
| PE20010753A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
| ES2201552T3 (es) | Agonistas del receptor a1 de la adenosina. | |
| ES2269113T3 (es) | Sintesis mejorada de -2.2.1 / biciclo-nucleosidos. | |
| PE20000280A1 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol | |
| KR930004276A (ko) | 치환된 헤테로사이클류 | |
| HRP20030565B1 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
| EA200200770A1 (ru) | Производные пурина | |
| PE27499A1 (es) | Derivados del 2-(purin-9-il)-tetrahidrofuran-3,4-diol | |
| DE60206756D1 (de) | Purin derivate als a2b adenosin rezeptor antagonisten | |
| HRP20050417A2 (en) | Antiviral nucleoside derivatives | |
| KR960703622A (ko) | 단백질 티로신 키나아제 억제제의 프로드러그(prodrugs of protein tyrosine kinase inhibitors) | |
| NO20025651D0 (no) | Adenosin A2A-reseptorantagonister | |
| AR040500A1 (es) | Inhibidores de cinasas | |
| RU2008131324A (ru) | Борсодержащие малые молекулы | |
| DK1392312T3 (da) | Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister | |
| KR920702223A (ko) | 정신병 치료제로서의 1-사이클로알킬피페리딘 | |
| PE20000426A1 (es) | Uso de dihidropirimidinas como medicamento y nuevas sustancias | |
| DK0560794T3 (da) | Substituerede 1,3-oxathiolaner med antivirale egenskaber | |
| PE20070179A1 (es) | Derivados de purina como agonistas del receptor de adenosina a2 | |
| RU2007137990A (ru) | Производные аденозина, обладающие активностью а2а рецептора | |
| FI970317A0 (fi) | Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |